{"id":2164,"date":"2025-01-14T16:38:58","date_gmt":"2025-01-14T16:38:58","guid":{"rendered":"https:\/\/ocvigilance.com\/?p=2164"},"modified":"2025-01-14T16:38:59","modified_gmt":"2025-01-14T16:38:59","slug":"the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials","status":"publish","type":"post","link":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/","title":{"rendered":"The EMA has published version 1.4 of the &#8216;Extended Eudravigilance Medicinal Product Report (XEVPRM) user guidance for sponsors of clinical trials"},"content":{"rendered":"<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">T2,T3 <\/p><\/div>\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-a89b3969 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button has-custom-width wp-block-button__width-50\"><a class=\"wp-block-button__link has-background wp-element-button\" href=\"https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-chapter-2-format-electronic-submission-veterinary-medicinal-product-information_en.pdf\" style=\"border-radius:5px;background-color:#004667\">More information<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>T2,T3<\/p>\n","protected":false},"author":3,"featured_media":1452,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23],"tags":[],"class_list":["post-2164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicines-for-human-use"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EMA publishes new update of: List of European Union reference dates and frequency of submission of periodic safety update reports (T2,T3).<\/title>\n<meta name=\"description\" content=\"All the information! The EMA has published a new update (v. 138) of the &#039;List of European Union reference dates and frequency of submission of periodic safety update reports&#039; (T2,T3).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA publishes new update of: List of European Union reference dates and frequency of submission of periodic safety update reports (T2,T3).\" \/>\n<meta property=\"og:description\" content=\"All the information! The EMA has published a new update (v. 138) of the &#039;List of European Union reference dates and frequency of submission of periodic safety update reports&#039; (T2,T3).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"OC Vigilance\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-14T16:38:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-14T16:38:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-una-nueva-actualizacion-v.-138-de-la-List-of-European-Union-reference-dates-and-frequency-of-submission-of-periodic-safety-update-reports-T2T3.-.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1618\" \/>\n\t<meta property=\"og:image:height\" content=\"1079\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Maria Lopez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maria Lopez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/\"},\"author\":{\"name\":\"Maria Lopez\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#\\\/schema\\\/person\\\/e70f84d0be2a5c933347d118cb459dde\"},\"headline\":\"The EMA has published version 1.4 of the &#8216;Extended Eudravigilance Medicinal Product Report (XEVPRM) user guidance for sponsors of clinical trials\",\"datePublished\":\"2025-01-14T16:38:58+00:00\",\"dateModified\":\"2025-01-14T16:38:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/\"},\"wordCount\":22,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/La-EMA-ha-publicado-una-nueva-actualizacion-v.-138-de-la-List-of-European-Union-reference-dates-and-frequency-of-submission-of-periodic-safety-update-reports-T2T3.-.jpeg\",\"articleSection\":[\"Medicines for human use\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/\",\"name\":\"EMA publishes new update of: List of European Union reference dates and frequency of submission of periodic safety update reports (T2,T3).\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/La-EMA-ha-publicado-una-nueva-actualizacion-v.-138-de-la-List-of-European-Union-reference-dates-and-frequency-of-submission-of-periodic-safety-update-reports-T2T3.-.jpeg\",\"datePublished\":\"2025-01-14T16:38:58+00:00\",\"dateModified\":\"2025-01-14T16:38:59+00:00\",\"description\":\"All the information! The EMA has published a new update (v. 138) of the 'List of European Union reference dates and frequency of submission of periodic safety update reports' (T2,T3).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/La-EMA-ha-publicado-una-nueva-actualizacion-v.-138-de-la-List-of-European-Union-reference-dates-and-frequency-of-submission-of-periodic-safety-update-reports-T2T3.-.jpeg\",\"contentUrl\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/La-EMA-ha-publicado-una-nueva-actualizacion-v.-138-de-la-List-of-European-Union-reference-dates-and-frequency-of-submission-of-periodic-safety-update-reports-T2T3.-.jpeg\",\"width\":1618,\"height\":1079},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The EMA has published version 1.4 of the &#8216;Extended Eudravigilance Medicinal Product Report (XEVPRM) user guidance for sponsors of clinical trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#website\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/\",\"name\":\"OC Vigilance\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ocvigilance.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#organization\",\"name\":\"OC Vigilance\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/logo-oscuro.png\",\"contentUrl\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/logo-oscuro.png\",\"width\":250,\"height\":100,\"caption\":\"OC Vigilance\"},\"image\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#\\\/schema\\\/person\\\/e70f84d0be2a5c933347d118cb459dde\",\"name\":\"Maria Lopez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/litespeed\\\/avatar\\\/62c29870d6c7a561dc2b34f4345149c7.jpg?ver=1775187558\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/litespeed\\\/avatar\\\/62c29870d6c7a561dc2b34f4345149c7.jpg?ver=1775187558\",\"contentUrl\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/litespeed\\\/avatar\\\/62c29870d6c7a561dc2b34f4345149c7.jpg?ver=1775187558\",\"caption\":\"Maria Lopez\"},\"url\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/author\\\/maria-lopez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EMA publishes new update of: List of European Union reference dates and frequency of submission of periodic safety update reports (T2,T3).","description":"All the information! The EMA has published a new update (v. 138) of the 'List of European Union reference dates and frequency of submission of periodic safety update reports' (T2,T3).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"EMA publishes new update of: List of European Union reference dates and frequency of submission of periodic safety update reports (T2,T3).","og_description":"All the information! The EMA has published a new update (v. 138) of the 'List of European Union reference dates and frequency of submission of periodic safety update reports' (T2,T3).","og_url":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/","og_site_name":"OC Vigilance","article_published_time":"2025-01-14T16:38:58+00:00","article_modified_time":"2025-01-14T16:38:59+00:00","og_image":[{"width":1618,"height":1079,"url":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-una-nueva-actualizacion-v.-138-de-la-List-of-European-Union-reference-dates-and-frequency-of-submission-of-periodic-safety-update-reports-T2T3.-.jpeg","type":"image\/jpeg"}],"author":"Maria Lopez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Maria Lopez","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/"},"author":{"name":"Maria Lopez","@id":"https:\/\/ocvigilance.com\/#\/schema\/person\/e70f84d0be2a5c933347d118cb459dde"},"headline":"The EMA has published version 1.4 of the &#8216;Extended Eudravigilance Medicinal Product Report (XEVPRM) user guidance for sponsors of clinical trials","datePublished":"2025-01-14T16:38:58+00:00","dateModified":"2025-01-14T16:38:59+00:00","mainEntityOfPage":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/"},"wordCount":22,"commentCount":0,"publisher":{"@id":"https:\/\/ocvigilance.com\/#organization"},"image":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-una-nueva-actualizacion-v.-138-de-la-List-of-European-Union-reference-dates-and-frequency-of-submission-of-periodic-safety-update-reports-T2T3.-.jpeg","articleSection":["Medicines for human use"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/","url":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/","name":"EMA publishes new update of: List of European Union reference dates and frequency of submission of periodic safety update reports (T2,T3).","isPartOf":{"@id":"https:\/\/ocvigilance.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-una-nueva-actualizacion-v.-138-de-la-List-of-European-Union-reference-dates-and-frequency-of-submission-of-periodic-safety-update-reports-T2T3.-.jpeg","datePublished":"2025-01-14T16:38:58+00:00","dateModified":"2025-01-14T16:38:59+00:00","description":"All the information! The EMA has published a new update (v. 138) of the 'List of European Union reference dates and frequency of submission of periodic safety update reports' (T2,T3).","breadcrumb":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/#primaryimage","url":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-una-nueva-actualizacion-v.-138-de-la-List-of-European-Union-reference-dates-and-frequency-of-submission-of-periodic-safety-update-reports-T2T3.-.jpeg","contentUrl":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-una-nueva-actualizacion-v.-138-de-la-List-of-European-Union-reference-dates-and-frequency-of-submission-of-periodic-safety-update-reports-T2T3.-.jpeg","width":1618,"height":1079},{"@type":"BreadcrumbList","@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-4-of-the-extended-eudravigilance-medicinal-product-report-xevprm-user-guidance-for-sponsors-of-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ocvigilance.com\/en\/"},{"@type":"ListItem","position":2,"name":"The EMA has published version 1.4 of the &#8216;Extended Eudravigilance Medicinal Product Report (XEVPRM) user guidance for sponsors of clinical trials"}]},{"@type":"WebSite","@id":"https:\/\/ocvigilance.com\/#website","url":"https:\/\/ocvigilance.com\/","name":"OC Vigilance","description":"","publisher":{"@id":"https:\/\/ocvigilance.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ocvigilance.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ocvigilance.com\/#organization","name":"OC Vigilance","url":"https:\/\/ocvigilance.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ocvigilance.com\/#\/schema\/logo\/image\/","url":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/logo-oscuro.png","contentUrl":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/logo-oscuro.png","width":250,"height":100,"caption":"OC Vigilance"},"image":{"@id":"https:\/\/ocvigilance.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ocvigilance.com\/#\/schema\/person\/e70f84d0be2a5c933347d118cb459dde","name":"Maria Lopez","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ocvigilance.com\/wp-content\/litespeed\/avatar\/62c29870d6c7a561dc2b34f4345149c7.jpg?ver=1775187558","url":"https:\/\/ocvigilance.com\/wp-content\/litespeed\/avatar\/62c29870d6c7a561dc2b34f4345149c7.jpg?ver=1775187558","contentUrl":"https:\/\/ocvigilance.com\/wp-content\/litespeed\/avatar\/62c29870d6c7a561dc2b34f4345149c7.jpg?ver=1775187558","caption":"Maria Lopez"},"url":"https:\/\/ocvigilance.com\/en\/author\/maria-lopez\/"}]}},"_links":{"self":[{"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/posts\/2164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/comments?post=2164"}],"version-history":[{"count":1,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/posts\/2164\/revisions"}],"predecessor-version":[{"id":2165,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/posts\/2164\/revisions\/2165"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/media\/1452"}],"wp:attachment":[{"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/media?parent=2164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/categories?post=2164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/tags?post=2164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}